208 related articles for article (PubMed ID: 18339186)
1. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
2. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
4. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
[TBL] [Abstract][Full Text] [Related]
6. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
7. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey.
Ramaswami U; Whybra C; Parini R; Pintos-Morell G; Mehta A; Sunder-Plassmann G; Widmer U; Beck M;
Acta Paediatr; 2006 Jan; 95(1):86-92. PubMed ID: 16498740
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
10. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
12. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
14. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
15. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Banikazemi M; Ullman T; Desnick RJ
Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease.
Tarabuso AL
Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
[TBL] [Abstract][Full Text] [Related]
20. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data.
Dehout F; Schwarting A; Beck M; Mehta A; Ricci R; Widmer U;
Acta Paediatr Suppl; 2003 Dec; 92(443):14-5; discussion 5. PubMed ID: 14989460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]